Alzheimer’s disease, related dementia diagnoses up in Medicare decedents
Apr 01, 2022
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.
Pricey Alzheimer drug drives spike in Medicare B premium: Officials
Nov 15, 2021
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
Memo to memory care communities: Don’t bogart that medicine, and lighten up
By
John O'Connor
Jul 25, 2018
Could synthetic marijuana and bright lights be the next big things in dementia care? New findings revealed at the Alzheimer’s Association’s International Conference in Chicago suggest both...
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Assisted living residents with dementia had higher all-cause mortality during pandemic
By
Alicia Lasek
Aug 11, 2022
Assisted living residents with dementia were more likely to die from any cause in the early months of the pandemic than assisted living residents without dementia, a new study has found.
New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.
A Q&A with NIC’s Robert Kramer
By
John Hall
Sep 13, 2016
Robert G. Kramer, founder and CEO of the National Investment Center for Seniors Housing & Care, recently spoke with McKnight’s about the current state and future prospects of independent living,...
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
More news for Wednesday, Nov. 16
Nov 15, 2016
Medicare isn’t really going broke … What the Trump presidency means for senior citizens … Ability to recognize and recall odors may identify those at risk for Alzheimer’s disease...
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.